ARPA-H Launches Initiative to Revolutionize Cancer Treatment
The Advanced Research Projects Agency for Health (ARPA-H), under the U.S. Department of Health and Human Services (HHS), has introduced an ambitious project named One Comprehensive Universal Radiotherapy for Everyone (1-CURE). This program aims to create a universally applicable radiotherapy treatment that can address all cancer types, including complex metastatic and pediatric cancers, through a single, low-cost procedure.
Cancer remains a leading cause of morbidity and mortality in the United States, affecting over 2 million individuals annually and resulting in approximately 600,000 deaths each year. The disease significantly burdens children, as it is the primary cause of disease-related death in this demographic. Current cancer treatments involve prolonged therapies that can be both physically taxing and financially draining for patients and their families.
Robert F. Kennedy, Jr., Secretary of HHS, emphasized the program's potential to alleviate the burdens associated with cancer treatment, stating, “Every year, millions of Americans hear ‘you have cancer’ and face grueling treatment and crushing costs." He highlighted the program's goal of developing cost-effective radiotherapy that can effectively treat multiple cancers with a single intervention.
A significant portion of cancer patients in the United States experience high treatment costs, often leading to deferred or omitted care that is critical for survival. Although radiotherapy plays a critical role in cancer management, especially in pediatric cases, its effectiveness is frequently compromised when tumors develop resistance, and adverse side effects are common.
Alicia Jackson, Ph.D., ARPA-H Director, noted 1-CURE's transformative potential, saying, “1-CURE is designed to fundamentally change what it means to get a cancer diagnosis. By uniting cutting-edge radiotherapy technologies with smart biomaterials, this program aims to move patients from months of grueling, expensive treatment to a single, highly targeted intervention."
The 1-CURE initiative focuses on advancing two primary technological frameworks: smart radiotherapy biomaterials (SRBs) and the abscopal treatment planning system (ATPS), integrated with ultra-high dose rate radiotherapy (FLASH-RT). While traditional radiotherapy requires numerous sessions over months at lower doses, FLASH-RT is capable of administering highly concentrated doses in under a second, potentially causing less harm to healthy tissues. This could be a game-changer for treating resistant or metastatic tumors.
Wilfred Ngwa, Ph.D., 1-CURE Program Manager, discussed the program’s objectives: developing a universal radiotherapy method effective against all cancers by combining FLASH-RT, which exposes tumor markers, with immune-boosting nanomaterials. This combination aims to train the immune system to eliminate tumors and prevent their recurrence.
The program calls for proposals focusing on two key areas: developing multifunctional immune-enhancing radiotherapy biomaterials and utilizing AI-driven planning systems to optimize treatment while minimizing side effects. ARPA-H encourages the formation of multidisciplinary teams, comprising experts in physics, immunology, materials science, AI, engineering, clinical oncology, and advanced manufacturing, to achieve the program's comprehensive objectives.